Our quantitative LC-MS/MS data showed no indication of relevantly altered GATA3 levels (Supplementary Fig. 10d), which could be explained by IHC-specific confounders (such as more epitope-degraded samples with more advanced, frequently inflamed cancers). This evidence concerns the gene GATA3 and cancer.